Costs ‐ not reported · inpatients who are mildly or seriously malnourished or at risk of being malnourished, elderly patients at risk of developing pressure ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · inpatients who are mildly or seriously malnourished or at risk of being malnourished, elderly patients at risk of developing pressure ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of pressure ulcers · patients (> 65 years) following hip fracture; patients with a recent stroke
Summary of findings table ‐ Protein showed no clear difference in incidence of pressure ulcers compared with standard diet (low certainty).
1 finding from 1 review
Time to pressure ulcer development · patients (> 65 years) following hip fracture; patients with a recent stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability of nutritional supplements ‐ not reported · patients (> 65 years) following hip fracture; patients with a recent stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with heart failure
Exercise‐based cardiac rehabilitation showed no clear difference in all‐cause mortality compared with usual care (low certainty).
1 finding from 1 review
Hospital admissions · adults with heart failure
Exercise‐based cardiac rehabilitation probably leads to lower all‐cause hospital admissions compared with usual care (moderate certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults with heart failure
Exercise‐based cardiac rehabilitation showed no clear difference in HF‐related hospital admissions compared with usual care (moderate certainty).
1 finding from 1 review
HRQoL (MLWHF only) · adults with heart failure
1 finding from 1 review
HRQoL (all measurement scales) · adults with heart failure
1 finding from 1 review
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in clinical vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 3.03 [0.32, 28.44]
Studies not reported
Low
Wrist fractures · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.9 [0.13, 6.04]
Studies not reported
Very low
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.56 [0.2, 1.61]
Studies not reported
Moderate
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Wrist fractures · postmenopausal women at lower risk of fractures1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 1.41 [0.81, 2.47]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Clinical vertebral fractures · postmenopausal women with a higher risk for fracturesa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found